Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene

키워드

참고문헌 (41)

1. Kutzler MA, "DNA vaccines: ready for prime time?", Nat Rev Genet, 9, pp.776~788 (2008)
2. Liu MA, "DNA vaccines: a review", J Intern Med, 253, pp.404~410 (2003)
3. Belakova J, "are they still just a powerful tool for the future?", Arch Immunol Ther Exp, 55, pp.387~398 (2007)
4. Abdulhaqq SA, "DNA vaccines: developing new strategies to enhance immune responses", Immunol Res, 42, pp.219~232 (2008)
5. Liu MA, "DNA vaccines:recent developments and future possibilities", Hum Gene Ther, 17, pp.1051~1061 (2006)
6. Lee AH, "DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses", Vaccine, 17, pp.473~479 (1999)
7. Suh YS, "Enhancement of VP1-specific immune responses and protection against EMCV-K challenge by co-delivery of IL-12 DNA with VP1 DNA vaccine", Vaccine, 19, pp.1891~1898 (2001)
8. Yu DH, "A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector", Vaccine, 25, pp.6744~6754 (2007)
9. Lee SW, "Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colonystimulating factor gene", J Virol, 72, pp.8430~8436 (1998)
10. Maksaereekul S, "Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV", Vaccine, 27, pp.3754~3765 (2009)
11. Gomez CE, "Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens", Vaccine, 27, pp.3165~3174 (2009)
12. Maue AC, "CD80 and CD86, but not CD154,augment DNA vaccine-induced protection in experimental bovine tuberculosis", Vaccine, 23, pp.769~779 (2004)
13. Stone GW, "Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines", J Virol, 80, pp.1762~1772 (2006)
14. Salgaller ML, "Use of cellular and cytokine adjuvants in the immunotherapy of cancer", J Surg Oncol, 68, pp.122~138 (1998)
15. Shiver JW, "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", Nature, 415, pp.331~335 (2002)
16. Chaudhry UI, "Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth", Cancer Res, 66, pp.10497~10504 (2006)
17. Paget C, "Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides", J Immunol, 182, pp.1846~1853 (2009)
18. Kojima Y, "Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine", Vaccine, 20, pp.2857~2865 (2002)
19. Sato Y, "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization", Science, 273, pp.352~354 (1996)
20. Seaman MS, "Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys", J Virol, 79, pp.2956~2963 (2005)
21. Kjerrstrom A, "Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines", Virology, 284, pp.46~61 (2001)
22. Grifantini R, "Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid", Eur J Immunol, 28, pp.1225~1232 (1998)
23. Sin JI, "Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene", Vaccine, 15, pp.1827~1833 (1997)
24. Song MK, "Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice", J Virol, 74, pp.2920~2925 (2000)
25. Power CA, "A valid ELISPOT assay for enumeration of exvivo, antigen-specific, IFNgamma-producing T cells", J Immunol Methods, 227, pp.99~107 (1999)
26. Kurts C, "Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction", J Exp Med, 188, pp.409~414 (1998)
27. Bot A, "Enhanced protection against influenza virus of mice immunized as newborns with a mixture of plasmids expressing hemagglutinin and nucleoprotein", Vaccine, 16, pp.1675~1682 (1998)
28. Murali-Krishna K, "Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection", Immunity, 8, pp.177~187 (1998)
29. Kaech SM, "Effector and memory T-cell differentiation: implications for vaccine development", Nat Rev Immunol, 2, pp.251~262 (2002)
30. Li M, "Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo", J Immunol, 166, pp.6099~6103 (2001)
31. Fu TM, "Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge", J Immunol, 162, pp.4163~4170 (1999)
32. Justewicz DM, "Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin", J Virol, 69, pp.7712~7717 (1995)
33. Fu TM, "cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization", J Virol, 71, pp.2715~2721 (1997)
34. Lee SW, "IL-6 induces long-term protective immunity against a lethal challenge of influenza virus", Vaccine, 17, pp.490~496 (1999)
35. Chen W, "Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses", Immunity, 12, pp.83~93 (2000)
36. Potter P, "Differential processing and presentation of the H-2D(b)-restricted epitope from two different strains of influenza virus nucleoprotein", J Gen Virol, 82, pp.1069~1074 (2001)
37. Yewdell JW, "Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses", Annu Rev Immunol, 17, pp.51~88 (1999)
38. Krieg AM, "CpG motifs in bacterial DNA and their immune effects", Annu Rev Immunol, 20, pp.709~760 (2002)
39. Fomsgaard A, "Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen", Scand J Immunol, 47(4), pp.289~295 (1998)
40. Cella M, "Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation", J Exp Med, 184(2), pp.747~752 (1996)
41. Ramanathan S, "Antigen-nonspecific activation of CD8＋ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer", Arch Immunol Ther Exp, 56(5), pp.311~323 (2008)

관련 논문AI추천